Mylan announced the launch of Dimethyl Fumarate Delayed-Release Capsules, the first Food and Drug Administration (FDA)-approved therapeutically equivalent, substitutable generic of Tecfidera® (Biogen).
Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
The product is supplied as 120mg and 240mg delayed-release capsules.
“The launch of the first generic Tecfidera is yet another prime example of Mylan’s fundamental commitment to bringing more access to patients worldwide, in this particular case through our important continued support of the MS community, while helping to provide immediate and substantial savings for the US healthcare system,” said Mylan CEO Heather Bresch.
For more information visit mylan.com.
Mylan brings critical access to the multiple sclerosis community by launching a more affordable treatment option through a first generic to Tecfidera®. https://www.prnewswire.com/news-releases/mylan-brings-critical-access-to-the-multiple-sclerosis-community-by-launching-a-more-affordable-treatment-option-through-a-first-generic-to-tecfidera-301114591.html. Accessed August 19, 2020.
This article originally appeared on MPR